{"id":2956,"date":"2015-02-15T15:08:21","date_gmt":"2015-02-15T15:08:21","guid":{"rendered":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?p=2956"},"modified":"2015-02-10T15:09:00","modified_gmt":"2015-02-10T15:09:00","slug":"linezolid-bei-multiresistenter-tuberkulose-2","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/linezolid-bei-multiresistenter-tuberkulose-2\/","title":{"rendered":"Linezolid bei multiresistenter Tuberkulose"},"content":{"rendered":"<p>AMB 2012, 46, 85b Linezolid bei multiresistenter Tuberkulose Linezolid (Zyvoxid\u00ae) wird haupts\u00e4chlich zur Behandlung Vancomycin-resistenter Infektionen mit gram-positiven Keimen eingesetzt (1, vgl. auch 2). Es liegen Daten zu Sicherheitsprofil und UAW bei einer Behandlung bis zu 28 Tage vor, die akzeptabel sind (3). Die Datenlage zur Therapie mit Linezolid \u00fcber diesen Zeitraum hinaus ist ungen\u00fcgend. [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AMB 2012, 46, 85b Linezolid bei multiresistenter Tuberkulose Linezolid (Zyvoxid\u00ae) wird haupts\u00e4chlich zur Behandlung Vancomycin-resistenter Infektionen mit gram-positiven Keimen eingesetzt (1, vgl. auch 2). Es liegen Daten zu Sicherheitsprofil und UAW bei einer Behandlung bis zu 28 Tage vor, die akzeptabel sind (3). Die Datenlage zur Therapie mit Linezolid \u00fcber diesen Zeitraum hinaus ist ungen\u00fcgend. [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[412,648,649],"class_list":["post-2956","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-linezolid","tag-lungentuberkulose","tag-tuberkulose"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Linezolid bei multiresistenter Tuberkulose<\/title>\n<meta name=\"description\" content=\"Linezolid bei multiresistenter Tuberkulose - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken --&gt;\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/linezolid-bei-multiresistenter-tuberkulose-2\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Linezolid bei multiresistenter Tuberkulose\" \/>\n<meta property=\"og:description\" content=\"Linezolid bei multiresistenter Tuberkulose - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken --&gt;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/linezolid-bei-multiresistenter-tuberkulose-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2015-02-15T15:08:21+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg\" \/>\n<meta name=\"author\" content=\"henk-amb\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"henk-amb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"4\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/linezolid-bei-multiresistenter-tuberkulose-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/linezolid-bei-multiresistenter-tuberkulose-2\\\/\"},\"author\":{\"name\":\"henk-amb\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"headline\":\"Linezolid bei multiresistenter Tuberkulose\",\"datePublished\":\"2015-02-15T15:08:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/linezolid-bei-multiresistenter-tuberkulose-2\\\/\"},\"wordCount\":748,\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/linezolid-bei-multiresistenter-tuberkulose-2\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\",\"keywords\":[\"Linezolid\",\"Lungentuberkulose\",\"Tuberkulose\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/linezolid-bei-multiresistenter-tuberkulose-2\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/linezolid-bei-multiresistenter-tuberkulose-2\\\/\",\"name\":\"Linezolid bei multiresistenter Tuberkulose\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/linezolid-bei-multiresistenter-tuberkulose-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/linezolid-bei-multiresistenter-tuberkulose-2\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\",\"datePublished\":\"2015-02-15T15:08:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"description\":\"Linezolid bei multiresistenter Tuberkulose - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/linezolid-bei-multiresistenter-tuberkulose-2\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/linezolid-bei-multiresistenter-tuberkulose-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/linezolid-bei-multiresistenter-tuberkulose-2\\\/#primaryimage\",\"url\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\",\"contentUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/linezolid-bei-multiresistenter-tuberkulose-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Linezolid bei multiresistenter Tuberkulose\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\",\"name\":\"henk-amb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"caption\":\"henk-amb\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Linezolid bei multiresistenter Tuberkulose","description":"Linezolid bei multiresistenter Tuberkulose - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/linezolid-bei-multiresistenter-tuberkulose-2\/","og_locale":"de_DE","og_type":"article","og_title":"Linezolid bei multiresistenter Tuberkulose","og_description":"Linezolid bei multiresistenter Tuberkulose - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/linezolid-bei-multiresistenter-tuberkulose-2\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2015-02-15T15:08:21+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","type":"","width":"","height":""}],"author":"henk-amb","twitter_misc":{"Verfasst von":"henk-amb","Gesch\u00e4tzte Lesezeit":"4\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/linezolid-bei-multiresistenter-tuberkulose-2\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/linezolid-bei-multiresistenter-tuberkulose-2\/"},"author":{"name":"henk-amb","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"headline":"Linezolid bei multiresistenter Tuberkulose","datePublished":"2015-02-15T15:08:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/linezolid-bei-multiresistenter-tuberkulose-2\/"},"wordCount":748,"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/linezolid-bei-multiresistenter-tuberkulose-2\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","keywords":["Linezolid","Lungentuberkulose","Tuberkulose"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/linezolid-bei-multiresistenter-tuberkulose-2\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/linezolid-bei-multiresistenter-tuberkulose-2\/","name":"Linezolid bei multiresistenter Tuberkulose","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/linezolid-bei-multiresistenter-tuberkulose-2\/#primaryimage"},"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/linezolid-bei-multiresistenter-tuberkulose-2\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","datePublished":"2015-02-15T15:08:21+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"description":"Linezolid bei multiresistenter Tuberkulose - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/linezolid-bei-multiresistenter-tuberkulose-2\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/linezolid-bei-multiresistenter-tuberkulose-2\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/linezolid-bei-multiresistenter-tuberkulose-2\/#primaryimage","url":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","contentUrl":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/linezolid-bei-multiresistenter-tuberkulose-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Linezolid bei multiresistenter Tuberkulose"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937","name":"henk-amb","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","caption":"henk-amb"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/2956","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=2956"}],"version-history":[{"count":1,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/2956\/revisions"}],"predecessor-version":[{"id":2957,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/2956\/revisions\/2957"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=2956"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=2956"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=2956"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}